Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder

被引:16
|
作者
May, Matthias [1 ]
Bastian, Patrick J. [2 ]
Burger, Maximilian
Bolenz, Christian [3 ]
Trojan, Lutz [3 ]
Herrmann, Edwin [4 ]
Wuelfing, Christian [4 ]
Mueller, Stefan C. [5 ]
Ellinger, Joerg [5 ]
Buchner, Alexander [2 ]
Stief, Christian G. [2 ]
Tilki, Derya [2 ]
Otto, Wolfgang
Hoefner, Thomas [6 ]
Hohenfellner, Markus [6 ]
Haferkamp, Axel [7 ]
Roigas, Jan [8 ]
Zacharias, Mario [9 ]
Wieland, Wolf F.
Fritsche, Hans-Martin
机构
[1] St Elisabeth Klinikum, Straubing, Germany
[2] LMU Munchen, Munich, Germany
[3] Univ Heidelberg, D-6800 Mannheim, Germany
[4] Univ Munster, Munster, Germany
[5] Univ Bonn, D-5300 Bonn, Germany
[6] Univ Heidelberg, Heidelberg, Germany
[7] Goethe Univ Frankfurt, Frankfurt, Germany
[8] Vivantes Kliniken Urban & Friedrichshain Berlin, Berlin, Germany
[9] Vivantes Klinikum AVK Berlin, Berlin, Germany
关键词
urothelial carcinoma; bladder cancer; radical cystectomy; pT0; stage; NEOADJUVANT CHEMOTHERAPY; LONG-TERM; CANCER; SURVIVAL; SPECIMEN; THERAPY; TUMORS; RISK;
D O I
10.1111/j.1464-410X.2011.10189.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To evaluate the characteristics and long-term outcome of patients with pT0 stage after radical cystectomy (RC) for urothelial carcinoma of the urinary bladder (UCB). PATIENTS AND METHODS Clinical and pathological records of 2403 patients treated with RC for UCB were collected in a multi-institutional database. The patients met the following criteria: clinical tumour stage cTa-cT2, cN0, cM0, no neoadjuvant chemotherapy or radiotherapy. Overall (OS) and cancer-specific survival rates (CSS) were calculated for the various clinical tumour stages in relation to their corresponding pathological tumour stage in the RC sample. Further to this, a multivariable prediction model was developed based onthe available clinical data to estimate the probability of tumour stage pT0. RESULTS The mean follow-up was 53 months and 132 patients (5.5%) were stage pT0. Patients withstage cT2-pT0 had a 5-year CSS of 87% vs 69% for cT2-pT2 (P = 0.012) and 57% for cT2-pT + (P < 0.001). In a multivariable Cox-model, stage pT0 led to a significant reduction of cancer-specific mortality (hazard ratio0.27; 95% confidence interval 0.12-0.61). A logistical regression model identified clinical tumour stage (advantage for non-invasive stages) and transurethral resection of the urinary bladder (TURB) time frame (advantage for more recent surgery) as independent predictors for stage pT0. CONCLUSIONS In muscle-invasive clinical tumour stages, patients with pathological tumour stage pT0 form a subgroup showing a significantly better CSS. A radical TURB is, assumedly, not causative of this improved survival rate, but rather it is that individual tumour characteristics allow for complete tumour eradication through the TURB procedure. A TURB with R0 resection is, as such, only a sign of a better tumour prognosis.
引用
收藏
页码:E278 / E283
页数:6
相关论文
共 50 条
  • [1] Stage pT0 after Radical Cystectomy: Are All Patients Equal?
    Chromecki, Thomas F.
    Cha, Eugene K.
    Shariat, Shahrokh F.
    [J]. EUROPEAN UROLOGY, 2011, 60 (03) : 603 - 604
  • [2] Prognostic value of vascular mimicry in patients with urothelial carcinoma of the bladder after radical cystectomy
    Zhou, Lin
    Chang, Yuan
    Xu, Le
    Son Tung Nguyen Hoang
    Liu, Zheng
    Fu, Qiang
    Lin, Zongming
    Xu, Jiejie
    [J]. ONCOTARGET, 2016, 7 (46) : 76214 - 76223
  • [3] Prognostic factors in patients with stage pT0/pT1/pTa in the radical cystectomy specimen
    Husillos-Alonso, Adrian
    Herranz-Amo, Felipe
    Subira-Rios, David
    Maria Diez-Cordero, Jose
    Moralejo-Garate, Mercedes
    Lopez-Lopez, Esther
    Pinero-Sanchez, Javier
    Ogaya-Pinies, Gabriel
    Lledo-Garcia, Enrique
    Hernandez-Fernandez, Carlos
    [J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2013, 66 (08): : 787 - 795
  • [4] Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy
    Rodler, Severin
    Buchner, Alexander
    Eismann, Lennert
    Schulz, Gerald Bastian
    Marcon, Julian
    Ledderose, Stephan
    Schlenker, Boris
    Stief, Christian G.
    Karl, Alexander
    Jokisch, Jan -Friedrich
    [J]. RESEARCH AND REPORTS IN UROLOGY, 2022, 14 : 281 - 290
  • [5] Stage pT0 after radical prostatectomy: a diagnostic dilemma
    Schirrmacher, Stephanie
    Kallidonis, Panagiotis
    Horn, Lars-Christian
    Nenning, Hans
    Rassler, Jorg
    Rai, Bhavan
    Do, Minh
    Liatsikos, Evangelos
    Stolzenburg, Jens-Uwe
    [J]. WORLD JOURNAL OF UROLOGY, 2015, 33 (09) : 1291 - 1296
  • [6] Prognostic Risk Stratification of Patients with Urothelial Carcinoma of the Bladder with Recurrence After Radical Cystectomy
    Nakagawa, Tohru
    Hara, Tomohiko
    Kawahara, Takashi
    Ogata, Yoshihiko
    Nakanishi, Hiroyuki
    Komiyama, Motokiyo
    Arai, Eri
    Kanai, Yae
    Fujimoto, Hiroyuki
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : 1275 - 1281
  • [7] Are bladder cancer patients with pT0 disease following radical cystectomy cured of cancer?
    George Thalmann
    [J]. Nature Clinical Practice Urology, 2006, 3 : 530 - 531
  • [8] Stage pT0 after radical prostatectomy: a diagnostic dilemma
    Stephanie Schirrmacher
    Panagiotis Kallidonis
    Lars-Christian Horn
    Hans Nenning
    Jörg Rassler
    Bhavan Rai
    Minh Do
    Evangelos Liatsikos
    Jens-Uwe Stolzenburg
    [J]. World Journal of Urology, 2015, 33 : 1291 - 1296
  • [9] Stage pT0 After Radical Prostatectomy With Previous Positive Biopsy Sets: A Multicenter Study
    Bessede, Thomas
    Soulie, Michel
    Mottet, Nicolas
    Rebillard, Xavier
    Peyromaure, Michael
    Ravery, Vincent
    Salomon, Laurent
    [J]. JOURNAL OF UROLOGY, 2010, 183 (03): : 958 - 962
  • [10] Clinical Outcomes of Patients with pT0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
    Fukuta, Fumimasa
    Masumori, Naoya
    Honma, Ichiya
    Muto, Masatoshi
    Ichihara, Koji
    Kitamura, Hiroshi
    Tsukamoto, Taiji
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (01) : 115 - 120